In this interactive patient case video, you'll meet a 62-year-old man with advanced renal cell carcinoma (RCC) and follow his journey through selection of 1st- and 2nd-line therapies and managing associated toxicities. Along the way, you'll answer questions at key points, and engage with clickable resources to deepen your understanding of:
- The different efficacy and safety profiles of targeted and immunotherapy treatments for RCC
- How to implement targeted therapies and immunotherapies into treatment strategies for advanced RCC
- Optimal sequencing of treatments
- The cause of toxicities and strategies to improve tolerability and manage side effects whilst maintaining optimal efficacy
Clinical Takeaways
-
Current clinical practice for patients with advanced ccRCC is frontline combination of immunotherapy-VEGFR TKI for IMDC intermediate/poor-risk patients
-
Adverse events can generally be managed through dosing strategies, enabling the patient to remain on first-line therapy as long as possible
-
Switching to 2nd-line therapy should ideally be at the point of disease progression